Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 51


Impact of HIV drug resistance on HIV/AIDS associated mortality, new infections and antiretroviral therapy program costs in sub-Saharan Africa.

Phillips AN, Stover J, Cambiano V, Nakagawa F, Jordan MR, Pillay D, Doherty M, Revill P, Bertagnolio S.

J Infect Dis. 2017 Feb 17. doi: 10.1093/infdis/jix089. [Epub ahead of print]


Poly drug use, chemsex drug use, and associations with sexual risk behaviour in HIV-negative men who have sex with men attending sexual health clinics.

Sewell J, Miltz A, Lampe FC, Cambiano V, Speakman A, Phillips AN, Stuart D, Gilson R, Asboe D, Nwokolo N, Clarke A, Collins S, Hart G, Elford J, Rodger AJ; Attitudes to and Understanding of Risk of Acquisition of HIV (AURAH) Study Group..

Int J Drug Policy. 2017 Feb 9;43:33-43. doi: 10.1016/j.drugpo.2017.01.001. [Epub ahead of print]


Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.

Phillips AN, Cambiano V, Nakagawa F, Bansi-Matharu L, Sow PS, Ehrenkranz P, Ford D, Mugurungi O, Apollo T, Murungu J, Bangsberg DR, Revill P.

PLoS One. 2016 Dec 15;11(12):e0167654. doi: 10.1371/journal.pone.0167654.


The HIV Care Cascade Among Female Sex Workers in Zimbabwe: Results of a Population-Based Survey From the Sisters Antiretroviral Therapy Programme for Prevention of HIV, an Integrated Response (SAPPH-IRe) Trial.

Cowan FM, Davey CB, Fearon E, Mushati P, Dirawo J, Cambiano V, Napierala Mavedzenge S, Hanisch D, Wong-Gruenwald R, Chemhuru M, Masuka N, Hatzold K, Mugurungi O, Busza J, Philips AN, Hargreaves JR.

J Acquir Immune Defic Syndr. 2017 Apr 1;74(4):375-382. doi: 10.1097/QAI.0000000000001255.


An epidemiological modelling study to estimate the composition of HIV-positive populations including migrants from endemic settings.

Nakagawa F; Writing Group on HIV Epidemiologic Estimates in Countries With Migrant Populations From High Prevalence Areas..

AIDS. 2017 Jan 28;31(3):417-425. doi: 10.1097/QAD.0000000000001329.


Point-of-Care Viral Load Testing for Sub-Saharan Africa: Informing a Target Product Profile.

Phillips AN, Cambiano V, Nakagawa F, Ford D, Apollo T, Murungu J, Rousseau C, Garnett G, Ehrenkranz P, Bansi-Matharu L, Vojnov L, Katz Z, Peeling R, Revill P.

Open Forum Infect Dis. 2016 Jul 29;3(3):ofw161.


Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy.

Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, van Lunzen J, Corbelli GM, Estrada V, Geretti AM, Beloukas A, Asboe D, Viciana P, Gutiérrez F, Clotet B, Pradier C, Gerstoft J, Weber R, Westling K, Wandeler G, Prins JM, Rieger A, Stoeckle M, Kümmerle T, Bini T, Ammassari A, Gilson R, Krznaric I, Ristola M, Zangerle R, Handberg P, Antela A, Allan S, Phillips AN, Lundgren J; PARTNER Study Group..

JAMA. 2016 Jul 12;316(2):171-81. doi: 10.1001/jama.2016.5148. Erratum in: JAMA. 2016 Aug 9;316(6):667. Erratum in: JAMA. 2016 Nov 15;316(19):2048.


Attitudes to and Understanding of Risk of Acquisition of HIV Over Time: Design and Methods for an Internet-based Prospective Cohort Study Among UK Men Who Have Sex With Men (the AURAH2 Study).

Sewell J, Speakman A, Phillips AN, Cambiano V, Lampe FC, Gilson R, Asboe D, Nwokolo N, Clarke A, Ogilvy A, Collins S, Rodger AJ.

JMIR Res Protoc. 2016 Jun 15;5(2):e128. doi: 10.2196/resprot.5582.


Identifying Key Drivers of the Impact of an HIV Cure Intervention in Sub-Saharan Africa.

Phillips AN, Cambiano V, Revill P, Nakagawa F, Lundgren JD, Bansi-Matharu L, Mabugu T, Sculpher M, Garnett G, Staprans S, Becker S, Murungu J, Lewin SR, Deeks SG, Hallett TB.

J Infect Dis. 2016 Jul 1;214(1):73-9. doi: 10.1093/infdis/jiw120.


Sustainable HIV treatment in Africa through viral-load-informed differentiated care.

Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa., Phillips A, Shroufi A, Vojnov L, Cohn J, Roberts T, Ellman T, Bonner K, Rousseau C, Garnett G, Cambiano V, Nakagawa F, Ford D, Bansi-Matharu L, Miners A, Lundgren JD, Eaton JW, Parkes-Ratanshi R, Katz Z, Maman D, Ford N, Vitoria M, Doherty M, Dowdy D, Nichols B, Murtagh M, Wareham M, Palamountain KM, Chakanyuka Musanhu C, Stevens W, Katzenstein D, Ciaranello A, Barnabas R, Braithwaite RS, Bendavid E, Nathoo KJ, van de Vijver D, Wilson DP, Holmes C, Bershteyn A, Walker S, Raizes E, Jani I, Nelson LJ, Peeling R, Terris-Prestholt F, Murungu J, Mutasa-Apollo T, Hallett TB, Revill P.

Nature. 2015 Dec 3;528(7580):S68-76. doi: 10.1038/nature16046.


A Method to Estimate the Size and Characteristics of HIV-positive Populations Using an Individual-based Stochastic Simulation Model.

Nakagawa F, van Sighem A, Thiebaut R, Smith C, Ratmann O, Cambiano V, Albert J, Amato-Gauci A, Bezemer D, Campbell C, Commenges D, Donoghoe M, Ford D, Kouyos R, Lodwick R, Lundgren J, Pantazis N, Pharris A, Quinten C, Thorne C, Touloumi G, Delpech V, Phillips A; SSOPHIE project working group in EuroCoord..

Epidemiology. 2016 Mar;27(2):247-56. doi: 10.1097/EDE.0000000000000423. Erratum in: Epidemiology. 2016 May;27(3):e24.


What do we know about the cost-effectiveness of HIV preexposure prophylaxis, and is it affordable?

Cambiano V, Miners A, Phillips A.

Curr Opin HIV AIDS. 2016 Jan;11(1):56-66. doi: 10.1097/COH.0000000000000217. Review.


Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis.

Phillips AN, Cambiano V, Miners A, Revill P, Pillay D, Lundgren JD, Bennett D, Raizes E, Nakagawa F, De Luca A, Vitoria M, Barcarolo J, Perriens J, Jordan MR, Bertagnolio S.

Lancet HIV. 2014 Nov;1(2):e85-93. doi: 10.1016/S2352-3018(14)70021-9.


Assessment of epidemic projections using recent HIV survey data in South Africa: a validation analysis of ten mathematical models of HIV epidemiology in the antiretroviral therapy era.

Eaton JW, Bacaër N, Bershteyn A, Cambiano V, Cori A, Dorrington RE, Fraser C, Gopalappa C, Hontelez JA, Johnson LF, Klein DJ, Phillips AN, Pretorius C, Stover J, Rehle TM, Hallett TB.

Lancet Glob Health. 2015 Oct;3(10):e598-608. doi: 10.1016/S2214-109X(15)00080-7.


Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM.

Phillips AN, Cambiano V, Miners A, Lampe FC, Rodger A, Nakagawa F, Brown A, Gill ON, De Angelis D, Elford J, Hart G, Johnson AM, Lundgren JD, Collins S, Delpech V.

AIDS. 2015 Sep 10;29(14):1855-62. doi: 10.1097/QAD.0000000000000767.


Projected Lifetime Healthcare Costs Associated with HIV Infection.

Nakagawa F, Miners A, Smith CJ, Simmons R, Lodwick RK, Cambiano V, Lundgren JD, Delpech V, Phillips AN.

PLoS One. 2015 Apr 22;10(4):e0125018. doi: 10.1371/journal.pone.0125018.


Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group.; Royal Free Hospital Clinic Cohort.; INSIGHT study group.; SMART study group.; ESPRIT study group..

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809.


Assessment of the Potential Impact and Cost-effectiveness of Self-Testing for HIV in Low-Income Countries.

Cambiano V, Ford D, Mabugu T, Napierala Mavedzenge S, Miners A, Mugurungi O, Nakagawa F, Revill P, Phillips A.

J Infect Dis. 2015 Aug 15;212(4):570-7. doi: 10.1093/infdis/jiv040.


Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings.

Phillips A, Cambiano V, Nakagawa F, Mabugu T, Miners A, Ford D, Pillay D, De Luca A, Lundgren J, Revill P.

PLoS One. 2014 Oct 7;9(10):e109148. doi: 10.1371/journal.pone.0109148. Erratum in: PLoS One. 2014;9(12):e115079. Magubu, Travor [corrected to Mabugu, Travor].

Supplemental Content

Loading ...
Support Center